title: Efficacy and tolerance of diclofenac sodium 0.1%, flurbiprofen 0.03%, and indomethacin 1.0% in controlling postoperative inflammation.
abstract: OBJECTIVE
  To compare the anti-inflammatory effect of diclofenac sodium 0.1% ophthalmic solution, flurbiprofen 0.03% ophthalmic solution, and indomethacin 1.0%.
  
  
  METHODS
  Department of Ophthalmology, University of Köln, and Bundesknappschaftskrankenhaus, Sulzbach, Germany.
  
  
  METHODS
  One hundred seventeen patients enrolled in this prospective, randomized, double-masked, and parallel-group study had phacoemulsification and intraocular lens implantation and received one of the three solutions. Preoperatively at day 1 and postoperatively at day 4 or 5 and day 12, 13, or 14, they were examined by slitlamp, applanation tonometry, and laser flare meter.
  
  
  RESULTS
  Anterior chamber flare reduction from baseline was significantly greater in the diclofenac group than in the flurbiprofen group (P = .022). Patients in the diclofenac group had significantly less burning and stinging than those in the flurbiprofen and indomethacin groups at postoperative days 4-5 and 12-14 (P = .001).
  
  
  CONCLUSIONS
  Diclofenac sodium appeared to be more potent than flurbiprofen in controlling intraocular inflammation after cataract surgery and appeared to be locally tolerated better than flurbiprofen and indomethacin.
authors.affiliation: Department of Ophthalmology, University of Köln, Germany.
authors.forename: M
authors.initials: M
authors.lastname: Diestelhorst
authors.forename: B
authors.initials: B
authors.lastname: Schmidl
authors.forename: W
authors.initials: W
authors.lastname: Konen
authors.forename: U
authors.initials: U
authors.lastname: Mester
authors.forename: P S
authors.initials: PS
authors.lastname: Raj
mesh_terms: D000287:Administration, Topical; D000328:Adult; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000008:administration & dosage* / Q000009:adverse effects; D004008:Diclofenac / Q000008:administration & dosage* / Q000009:adverse effects; D004311:Double-Blind Method; D009877:Endophthalmitis / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D005260:Female; D005480:Flurbiprofen / Q000008:administration & dosage* / Q000009:adverse effects; D005500:Follow-Up Studies; D006801:Humans; D007213:Indomethacin / Q000008:administration & dosage* / Q000009:adverse effects; D007910:Lenses, Intraocular / Q000009:adverse effects; D008297:Male; D009883:Ophthalmic Solutions; D018918:Phacoemulsification / Q000009:adverse effects; D011183:Postoperative Complications / Q000209:etiology / Q000473:pathology / Q000517:prevention & control*; D011446:Prospective Studies; D016896:Treatment Outcome
chemical_list: D000894:Anti-Inflammatory Agents, Non-Steroidal; D009883:Ophthalmic Solutions; D004008:Diclofenac; D005480:Flurbiprofen; D007213:Indomethacin